Empagliflozin significantly reduced left ventricular weight and ameliorated cardiac interstitial fibrosis and visceral adipocyte hypertrophy in prediabetic metabolic syndrome rats.
Does empagliflozin improve cardiac injury and adipocyte hypertrophy in prediabetic rats with metabolic syndrome?
In a prediabetic rat model of metabolic syndrome, empagliflozin reduced cardiac hypertrophy and visceral adiposity independently of blood pressure lowering.
Absolute Event Rate: 1363% vs 1465%
p-value: p=<0.05
BACKGROUND: The potential benefit of SGLT2 inhibitors in metabolic syndrome is with prediabetic stage unclear. This work was undertaken to investigate the non-glycemic effect of empagliflozin on metabolic syndrome rats with prediabetes. METHODS: SHR/NDmcr-cp(+/+) rats (SHRcp), a model of metabolic syndrome with prediabetes, were given empagliflozin for 10 weeks to examine the effects on urinary sodium and water balance, visceral and subcutaneous adipocyte, and cardiac injury. Further, the effect of empagliflozin on blood pressure and autonomic nervous system was continuously investigated by using radiotelemetry system. RESULTS: Empagliflozin significantly reduced urinary sodium and water balance of SHRcp only within 1 week of the treatment, but later than 1 week did not alter them throughout the treatment. Empagliflozin significantly reduced body weight of SHRcp, which was mainly attributed to the significant reduction of subcutaneous fat mass. Empagliflozin significantly reduced the size of visceral adipocytes and increased the number of smaller size of adipocytes, which was associated with the attenuation of oxidative stress. Empagliflozin ameliorated cardiac hypertrophy and fibrosis of SHRcp, in association with the attenuation of cardiac oxidative stress and inflammation. However, empagliflozin did not significantly change blood pressure, heart rate, sympathetic activity, or baroreceptor function, as evidenced by radiotelemetry analysis. CONCLUSIONS: Our present work provided the evidence that SGLT2 inhibition reduced visceral adipocytes hypertrophy and ameliorated cardiac injury in prediabetic metabolic syndrome rat, independently of diuretic effect or blood pressure lowering effect. Thus, SGLT2 inhibition seems to be a promising therapeutic strategy for prediabetic metabolic syndrome.
Kusaka et al. (Fri,) conducted a other in Prediabetic metabolic syndrome (n=24). Empagliflozin vs. Standard diet was evaluated on Left ventricular weight (mg) (p=<0.05). Empagliflozin significantly reduced left ventricular weight and ameliorated cardiac interstitial fibrosis and visceral adipocyte hypertrophy in prediabetic metabolic syndrome rats.